1.Fibromyalgia syndrome after comprehensive treatment of breast cancer: a case report.
Xia DING ; Yan LI ; Yiyi CUI ; Yingying SHEN ; Jianzhong GU ; Yong GUO
Journal of Zhejiang University. Medical sciences 2016;45(4):429-431
Fibromyalgia syndrome after comprehensive treatment of breast cancer is rare and seldom reported. Here we present a case of a 50-year-old female patient,who was admitted to the hospital because of generalized fibromyalgia for 3 months and brain metastasis after the right breast carcinoma surgery for 1 month, and the clinical diagnosis was brain metastasis from breast carcinoma combined with fibromyalgia syndrome. The fibromyalgia were relieved with proper symptomatic treatment but the patient eventually died of tumor progression.
Brain Neoplasms
;
mortality
;
secondary
;
Breast Neoplasms
;
complications
;
mortality
;
therapy
;
Carcinoma
;
mortality
;
therapy
;
Female
;
Fibromyalgia
;
diagnosis
;
etiology
;
therapy
;
Humans
;
Middle Aged
2.Gliomatosis Cerebri: Clinical Features and Prognosis.
Dae chuol JO ; Jeong Hyun HWANG ; Joo Kyung SUNG ; Sung Kyu HWANG ; In Suk HAMM ; Yeun Mook PARK ; Seung Yul BYUN ; Seung Lae KIM
Journal of Korean Neurosurgical Society 2001;30(12):1399-1405
OBJECTIVES: Gliomatosis cerebri is an uncommon primary brain tumor characterized by diffuse neoplastic proliferation of glial cells, with the preservation of the underlying cytoarchitecture. The aim of this study is to evaluate clinical features, outcome of surgical treatment and adjuvant therapy of gliomatosis cerebri. METHODS: Between Jan. 1990 and Dec. 2000, 12 patients were diagnosed with gliomatosis cerebri based on characteristic radiological and histological findings. The patients' age ranged from 18 to 77(mean 44) years and the male to female ratio was 7: 5. Nine patients underwent decompressive surgery and three, biopsy only. Postoperative radiation therapy was given in all cases except three. In addition to radiation therapy, four patients received chemotherapy. The mean duration of follow-up period was 18.8 months. RESULTS: The most common presenting symptom were seizure and motor weakness. The mean duration of symptom was 5.9 months. There was 5 bilateral lesions and tumor involved corpus callosum in 5, basal ganglia-thalamus in 4, and brain stem in 2. There was no operative mortality but four patients died during the follow-up. The mean survival period for 11 patients was 20.5 months from the time of diagnosis. In univariate analysis, the lesion involving corpus callosum, basal ganglia-thalamus and brain stem correlated significantly with the short length of survival(p<0.05). Also, postoperative radiation as a adjuvant therapy prolonged the patient's survival(p<0.05). CONCLUSIONS: In the management of gliomatosis cerebri patients, early detection by MR imaging, active management of increased intracranial pressure, decompressive surgical removal and postoperative adjuvant therapy such as radiation is thought to be a good treatment modality.
Biopsy
;
Brain Neoplasms
;
Brain Stem
;
Corpus Callosum
;
Diagnosis
;
Drug Therapy
;
Female
;
Follow-Up Studies
;
Humans
;
Intracranial Pressure
;
Magnetic Resonance Imaging
;
Male
;
Mortality
;
Neoplasms, Neuroepithelial*
;
Neuroglia
;
Prognosis*
;
Seizures
3.Validation of the Effectiveness and Safety of Temozolomide during and after Radiotherapy for Newly Diagnosed Glioblastomas: 10-year Experience of a Single Institution.
Jin Deok JOO ; Hansol KIM ; Young Hoon KIM ; Jung Ho HAN ; Chae Yong KIM
Journal of Korean Medical Science 2015;30(11):1597-1603
This study was performed to validate the effectiveness and safety of concurrent chemoradiotherapy and adjuvant therapy with temozolomide for newly diagnosed glioblastoma multiforme as a standard treatment protocol. Between 2004 and 2011, patients newly diagnosed with glioblastoma who were treated with temozolomide during concurrent chemoradiotherapy and adjuvant chemotherapy were included from a single institution and analyzed retrospectively. The primary endpoint was overall survival, and the secondary endpoints were progression-free survival, response, and safety. A total of 71 patients were enrolled in this study. The response rate was 41% (29/71), and the tumor control rate was 80% (57/71). In the 67 patients who completed the concurrent chemoradiotherapy with temozolomide, the median overall survival was 19 months and the 1- and 2-yr overall survival rates were 78.3% and 41.7%, respectively. The median progression free survival was 9 months, and the 1- and 2-yr progression free survival rates were 33.8% and 14.3%, respectively. The mean duration of survival after progression of disease in salvage treatment group was 11.9 (1.3-53.2) months. Concurrent chemoradiotherapy with temozolomide resulted in grade 3 or 4 hematologic toxic effects in 2.8% of the patients. The current protocol of temozolomide during and after radiation therapy is both effective and safe and is still appropriate as the standard protocol for treatment of glioblastoma. An active salvage treatment might be required for a better prognosis.
Adolescent
;
Adult
;
Aged
;
Aged, 80 and over
;
Antineoplastic Agents, Alkylating/administration & dosage
;
Brain Neoplasms/diagnosis/*mortality/*therapy
;
Chemoradiotherapy, Adjuvant/methods/mortality
;
Comorbidity
;
Dacarbazine/administration & dosage/*analogs & derivatives
;
Female
;
Glioblastoma/diagnosis/*mortality/*therapy
;
Hematologic Diseases/*mortality
;
Humans
;
Longitudinal Studies
;
Male
;
Middle Aged
;
Prevalence
;
Radiotherapy, Conformal/mortality
;
Republic of Korea/epidemiology
;
Risk Factors
;
Survival Rate
;
Treatment Outcome
;
Young Adult
4.Management Strategy of Spontaneous Subcortical Intracerebral Hemorrhage.
Kyu Won SHIM ; Yong Bae KIM ; Seung Kon HUH ; Sun Ho KIM ; Kyu Chang LEE
Korean Journal of Cerebrovascular Disease 2002;4(2):140-150
OBJECT: It is reported that spontaneous subcortical intracerebral hemorrhage consists about 10 to 44% of spontaneous intracerebral hemorrhage. Recently, spontaneous subcortical intracerebral hemorrhage due to the complication of the systemic disease has been increasing, and the selection of management strategy according to the cause of hemorrhage closely affected the management outcome. This study was designed to analyze the cause of spontaneous subcortical intracerebral hemorrhage and the outcome in order to establish the appropriate management strategy. SUBJECT: One hundred and seventy-nine cases of spontaneous subcortical intracerebral hemorrhage managed at Yonsei University Hospital from January 1998 to December 2000 were included in this study. Patients who suffered from subcortical intracerebral hemorrhage due to the ruptured intracranial aneurysm were excluded. The patient's sex, age, mental state on admission, neurologic condition, past history, systemic disease related to hemorrhage, location of hemorrhage, the diagnosis of intracranial or systemic disease, treatment methods, and clinical outcome were analyzed. Consciousness on admission was evaluated and scored based on Glasgow Coma Eye Motor Scale (GCEMS), which was the sum of eye response score and motor response score of the Glasgow Coma Scale. Patients were categorized into 4 groups according to GCEMS: Group 1 (10 points), Group 2 (8, 9 points), Group 3 (5-7 points), and Group 4 (2-4 points). The clinical outcome of the patient was evaluated based on Glasgow outcome scale (GOS). Differences in diagnostic procedure were present depending on the condition of the patients, thus the final diagnostic procedure was used to diagnose the reason behind bleeding. When accurate diagnosis was difficult to perform, the reasons with the highest likelihood were chosen. RESULTS: The patients corresponding to each group were as follow: 79 (44.1%) in Group 1, 35 (19.6%) in Group 2, 27 (15.1%) in Group 3, and 38 (21.2%) in Group 4. Fifty-five patients (30.7%) were hypertensive intracerebral hemorrhage, 45 patients (25.1%) had anticoagulant therapy and thrombocytopenia due to the systemic disease and bleeding diathesis after anticancer drug therapy, 23 patients (12.8%) had brain tumor including the metastatic tumor, 19 patients (10.6%) had arteriovenous malformation, 18 patients (10.1%) had postinfarct hemorrhages, 5 patients (2.8%) had infective endocarditis, 2 patients (1.1%) had cerebral vasculitis. Conservative treatment was done in 115 patients (64.2%), open craniotomy in 31 patients (17.3%), and catheter insertion in 33 patients (18.4%). Group 1 mainly had conservative treatment (58 patients, 73.4%), Group 2 and 3 had 12 patients (37.1%) and 16 patients (59.3%) each underwent open craniotomy respectively. In Group 4, conservative treatment was done for 24 patients (63.2%), and open craniotomy was done for only one patients among 14 patients treated surgically. Overall clinical outcome was: 77 patients (43.0%) in GOS 5, 21 (11.7%) in GOS 4, 14 (7.8%) in GOS 3, 11 (6.1%) in GOS 2, and 56 patients (31.3%) died. Poor neurological state (low GCEMS) on admission was closely related to mortality (Group 1, 7.6%; Group 2, 22.8%; Group 3, 45.0%; Group 4, 78.9%). CONCLUSION: The major causes of spontaneous subcortical intracerebral hemorrhage were hypertension, metastatic brain tumor, vascular malformation, and the bleeding tendency due to the systemic disease, complication of the anticancer drug, anticoagulant, and thrombolytics therapy. Conservative treatment could be considered for the patients with GCEMS 10, removal of hematoma by open craniotomy or catheter insertion for the patients with GCEMS 5-9, and the catheter insertion or deferring the active treatment could be considered for the patients with GCEMS 2-4.
Arteriovenous Malformations
;
Brain Neoplasms
;
Catheters
;
Cerebral Hemorrhage*
;
Coma
;
Consciousness
;
Craniotomy
;
Diagnosis
;
Disease Susceptibility
;
Drug Therapy
;
Endocarditis
;
Glasgow Coma Scale
;
Glasgow Outcome Scale
;
Hematoma
;
Hemorrhage
;
Humans
;
Hypertension
;
Intracranial Aneurysm
;
Intracranial Hemorrhage, Hypertensive
;
Mortality
;
Thrombocytopenia
;
Vascular Malformations
;
Vasculitis, Central Nervous System
5.High Risk Medulloblastoma in Childhood: Multidisciplinary Approach and Improved Outcome.
Joon Sup SONG ; Young Shin RA ; Seung Do AHN ; Shin Kwang KHANG ; Hyun Woo GOO ; Yoon Jung KIM ; Mee Jeong LEE ; Yoon Jeong KIM ; Thad GHIM
Korean Journal of Pediatric Hematology-Oncology 2004;11(2):187-194
PURPOSE: Medulloblastoma is the most common malignant brain tumor in childhood. The standard treatments are composed of tumor resection, irradiation and chemotherapy. In this study, we analysed the outcome of high risk medulloblastoma patients who were treated with surgical resection followed by craniospinal irradiation and chemotherapy utilizing cisplatin, vincristine, cyclophosphamide and etoposide. METHODS: We conducted a retrospective analysis of medical record of twenty-five patients with high risk medulloblastoma, treated from January 1998 to April 2004 in the Department of Pediatrics, Neurosurgery and Radiation Oncology at Asan Medical Center. RESULTS: The median age at diagnosis was 9 years and 10 month. The 2-year overall survival rate was 80%, and 2-year progression-free survival rate was 71%. Degree of surgical resections or residual tumor did not show statistically significant differences of survival rate, but there was difference depending on metastasis staging. The side effects of chemotherapy were grade IV hematologic toxicity (n=20), SIADH (n=2), and severe paralytic ileus (n=1). The long-term sequelae were endocrinopathy (n=6) that include growth failure, precocious puberty and hypothyroidism. Neurological complications such as mild mental retardation and ataxia occurred in seven patients. There was no treatment-related mortality. Four patients died of tumor progression. CONCLUSION: Patients with high risk medulloblastoma treated with surgical resection followed by radiation and chemotherapy as described here show satisfactory outcome. In this high risk group, metastasis staging correlated with outcome but the degree of surgical resection and presence or absence of residual tumor at primary site did not correlate with outcome.
Ataxia
;
Brain Neoplasms
;
Child
;
Chungcheongnam-do
;
Cisplatin
;
Craniospinal Irradiation
;
Cyclophosphamide
;
Diagnosis
;
Disease-Free Survival
;
Drug Therapy
;
Etoposide
;
Humans
;
Hypothyroidism
;
Inappropriate ADH Syndrome
;
Intellectual Disability
;
Intestinal Pseudo-Obstruction
;
Medical Records
;
Medulloblastoma*
;
Mortality
;
Neoplasm Metastasis
;
Neoplasm, Residual
;
Neurosurgery
;
Pediatrics
;
Puberty, Precocious
;
Radiation Oncology
;
Retrospective Studies
;
Survival Rate
;
Vincristine